GlassScriptPhysician profile
Samantha J Smith
NPI 1245887538
$1,984.52
in general payments reported to CMS, 2019-2025
23 companies · $984 in 2025
The $984 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.86 · 2022: $238 · 2023: $270 · 2024: $422 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $476.30 | 2024-2025 | Airsupra, Farxiga |
| Pfizer INC. | $181.74 | 2025 | |
| Novartis Pharmaceuticals Corporation | $170.22 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $149.55 | 2022 | |
| Lilly USA, LLC | $138.03 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $108.73 | 2025 | |
| Astellas Pharma US INC | $96.80 | 2021-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $94.20 | 2022-2023 | Xarelto |
| Exact Sciences Corporation | $82.28 | 2023-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $76.76 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $67.86 | 2023 | Camzyos |
| Novo Nordisk INC | $62.73 | 2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $51.38 | 2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.38 | 2022-2023 | Lifevest |
| Sanofi Pasteur INC. | $26.18 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $24.56 | 2021 | |
| Acadia Pharmaceuticals INC | $23.78 | 2024 | Daybue |
| Bayer Healthcare Pharmaceuticals INC. | $23.13 | 2025 | |
| Neurocrine Biosciences, INC. | $20.48 | 2024 | Ingrezza |
| Edwards Lifesciences Corporation | $20.28 | 2024 | |
| Corcept Therapeutics | $20.27 | 2025 | Korlym |
| Ultragenyx Pharmaceutical INC. | $19.49 | 2024 | Crysvita |
| Chiesi USA, INC. | $18.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.